Life Tech Targets Oxford's $173M Royalty Claim

Law360, New York (March 11, 2009, 12:00 AM EDT) -- Life Technologies Corp. is seeking to invalidate an Oxford Biomedical Research Inc. patent at the heart of a $173 million contract dispute over the patent’s method of purifying proteins in engineered DNA.

On Tuesday, Life Technologies, formerly Invitrogen Corp., filed an amended complaint in the U.S. District Court for the Middle District of Tennessee alleging Oxford’s patent is invalid because of prior art related to the purification of cytochrome P450 proteins.

While Life Technologies claims never to have practiced the method described in U.S. Patent Number...
To view the full article, register now.